![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Wednesday, May 27, 2009 1:19:27 PM
Phase III trials are generally the last stop on a drug's way from the lab to the pharmacy. These trials involve large subject groups and are designed to be the final assessment of a drug's efficacy and side effects. Phase III trials go one step further by comparing the drug candidate to the current standard treatment for a particular condition. If a drug is effective but shows no significant benefits over a treatment already in use, it can still be approved for production, though sales might not be as high as its developer had hoped. In the news, a drug that is proven to be safe and effective but that doesn't offer any advantages over the current "gold standard" treatment is often said to have "failed" the Phase III trials. While this something of a misnomer, it reflects the importance for pharmaceutical companies to develop innovative drugs that improve on existing treatment options.
Phase IV
Phase IV clinical trials occur after the approval and release of a new drug. These trials, which are sometimes not required, are used to further understand a drug's mechanism of action. For example, Phase IV trials often test the drug's interactions with other drugs and its effectiveness in certain populations that were not present in previous clinical trials. Additionally, drugs in this phase are monitored for long-term side effects that clinical trials were unable to detect. This can be important, since the relatively short duration of the clinical testing process doesn't allow for the observance of a drug's long-term impact on subjects. Vioxx, the blockbuster osteoarthritis drug made by Merck (MRK), is a well-known example of a drug recalled as a result of continual monitoring for safety.
Retrieved from "http://www.wikinvest.com/concept/Clinical_trials"
Recent DCTH News
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2024 12:00:53 PM
- Delcath Systems, Inc. Announces Positive Results from Independent Study on Liver-Directed Therapy for Uveal Melanoma Patients • Business Wire • 08/28/2024 08:01:00 PM
- Delcath Systems to Participate at the H.C. Wainwright 26th Annual Global Investment Conference • Business Wire • 08/28/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/28/2024 12:33:53 PM
- Delcath Systems, Inc. Announces Positive Outcomes from Independent Study on Hepatic Perfusion for Uveal Melanoma Patients • Business Wire • 08/27/2024 12:30:00 PM
- Delcath Systems, Inc. Announces Promising Results from Independent Study on Repeated Hepatic Chemosaturation for Liver Tumors • Business Wire • 08/26/2024 08:01:00 PM
- Delcath Systems Announces Poster Presentation at the 2024 ESMO Congress • Business Wire • 08/20/2024 12:30:00 PM
- Delcath Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) • Business Wire • 08/12/2024 08:01:00 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 08/06/2024 04:15:07 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/05/2024 08:36:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/05/2024 08:12:28 PM
- Delcath Systems Reports Second Quarter 2024 Results and Business Highlights • Business Wire • 08/05/2024 08:01:00 PM
- Delcath Systems Announces CMS Approval for NTAP for HEPZATO KIT™ • Business Wire • 08/05/2024 12:30:00 PM
- Delcath Systems to Participate in Upcoming Investor Conferences • Business Wire • 07/30/2024 08:01:00 PM
- Delcath Systems to Host Second Quarter 2024 Earnings Call • Business Wire • 07/22/2024 08:01:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/19/2024 08:06:00 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/09/2024 03:13:21 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 07/09/2024 01:01:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/29/2024 08:06:31 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 08:32:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 08:31:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 08:30:44 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 08:30:11 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 05/28/2024 08:28:10 PM
- Delcath Systems Announces Appointment of Bridget Martell, MA, MD to Delcath’s Board of Directors • Business Wire • 05/28/2024 01:30:00 PM
Element79 Gold Corp Appoints Warren Levy to Board of Directors • ELMGF • Aug 28, 2024 9:51 AM
Integrated Ventures Announces Strategic Entry Into Health & Wellness Industry with Focus on GLP-1 Products • INTV • Aug 28, 2024 8:30 AM
ELEMENT79 ANNOUNCES UPLISTING TO OTCQB VENTURE MARKET • ELMGF • Aug 26, 2024 10:03 AM
North Bay Resources Announces Gold Assays up to 2.2 Ounces per Ton, Fran Gold Project, British Columbia • NBRI • Aug 26, 2024 10:00 AM
PickleJar Unveils Latest Venue Managed Services Innovations in Upcoming Webinar • PKLE • Aug 23, 2024 1:11 PM
Element79 Gold Corp Provides Update on Nevada Portfolio • ELMGF • Aug 23, 2024 8:00 AM